Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Sees Significantly Higher Trading Volume

(NYSE:ZBH) by 933.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.

The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) hit a new 52-week high and has $143.99 target or 9.00% above today's $132.10 share price. FIL Ltd owned 0.44% of Zimmer Biomet Holdings worth $108,066,000 as of its most recent filing with the SEC.

Institutional investors have recently made changes to their positions in the company. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 0.44% since July 17, 2016 and is downtrending. Wells Fargo & Company reaffirmed a "market weight" rating on shares of Zimmer Biomet Holdings in a report on Friday. Canaccord Genuity reiterated a "buy" rating on shares of Zimmer Biomet Holdings in a research report on Friday, April 28th.

Currently, the analyst consensus on Zimmer Biomet Holdings is Moderate Buy and the average price target is $136.23, representing a 2.8% upside. First Allied Advisory Services Inc. now owns 6,738 shares of the medical equipment provider's stock valued at $695,000 after buying an additional 2,788 shares during the period. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider's stock worth $602,159,000 after buying an additional 987,398 shares during the last quarter. Finally, CENTRAL TRUST Co increased its position in Zimmer Biomet Holdings by 13.0% in the first quarter.

Zimmer Biomet Holdings, Inc. has a 1-year low of $95.63 and a 1-year high of $133.21. The company's 50-day moving average is $123.43 and its 200-day moving average is $117.75. Stifel Nicolaus reissued a "hold" rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. The firm had revenue of $1.98 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter in the prior year, the company posted $2.00 earnings per share. The firm's revenue was up 3.8% on a year-over-year basis. The medical equipment provider reported $2.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.11 by $0.02.

The company recently declared a dividend for shareholders payable on Friday the 28th of July 2017. The dividend will be $0.240 per share for the quarter which is $0.96 annualized. Investors of record on Friday, June 23rd will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, June 21st. Zimmer Biomet Holdings's payout ratio is now 39.67%. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post $8.52 EPS for the current year. "(NYSE:ZBH) Stake Boosted by Stratos Wealth Partners LTD." was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of United States and global trademark & copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/07/17/zimmer-biomet-holdings-inc-zbh-shares-bought-by-fil-ltd-updated-updated.html.

07/12/2017 - Zimmer Biomet Holdings, Inc. had its " rating reiterated by analysts at Needham & Company. August 23 investment analysts at Barclays kept the company rating at "Overweight" but raised the price expectation from $140.00 to $145.00.

07/12/2017 - Zimmer Biomet Holdings, Inc. was upgraded to " by analysts at Guggenheim. Cantor Fitzgerald added the stock to its research portfolio giving it an initial rating of "Neutral". Argus Research maintained Travelers Companies Inc (NYSE:TRV) on Monday, October 26 with "Buy" rating. The stock presently has an average rating of "Buy" and an average target price of $137.19.

In other news, VP Chad F. Phipps sold 6,200 shares of Zimmer Biomet Holdings stock in a transaction on Friday, May 5th. The shares were sold at an average price of $116.76, for a total transaction of $723,912.00. Following the completion of the sale, the insider now directly owns 381,886 shares in the company, valued at approximately $44,478,262.42. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have sold 111,262 shares of company stock worth $13,103,927. The shares were sold on April 27th for an average price of $116.56.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.